Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713334 · ClinicalTrials.gov registry record
Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling
A clinical trial of Tumor Genomic Profiling, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 495
- Enrollment target
- 1
- Study location
NCT02713334: Active study of Tumor Genomic Profiling, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02713334 is a study of Tumor Genomic Profiling that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 495 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02713334, a study of Tumor Genomic Profiling, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 495 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this protocol is to characterize cancer patients' responses to learning their secondary findings arising from tumor genomic profiling, and the process and outcomes of their decisions to communicate these results to their families.
Primary Outcome
Through quantitative (i.e., survey) assessments, the investigators will assess patients' emotional (both positive and negative) responses to receiving their secondary findings, and their perceptions regarding the utility of this information and communicating it to family.
Conditions Studied
Interventions
- BEHAVIORAL survey
- BEHAVIORAL semi-structured interview
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2016-02-25 |
| Est. Completion | 2026-02-25 |
What the registry record for NCT02713334 still lists
NCT02713334 is an observational study that tracks outcomes without assigning an intervention. The registered 495 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Tumor Genomic Profiling appearing as the primary indexed condition, and to 2 interventions - of which survey is the first listed.
NCT02713334 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02713334 about?
NCT02713334 is a clinical study titled "Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling". The objective of this protocol is to characterize cancer patients' responses to learning their secondary findings arising from tumor genomic profiling, and the process and outcomes of their decisions to communicate these results to their families.
What is the current status of trial NCT02713334?
This trial is currently active not recruiting. The enrollment target is 495 participants. The study started on 2016-02-25. Estimated completion is 2026-02-25.
What conditions does trial NCT02713334 study?
This clinical trial studies the following conditions: Tumor Genomic Profiling.
What interventions are being tested in trial NCT02713334?
The interventions under investigation include: survey (BEHAVIORAL), semi-structured interview (BEHAVIORAL).
Who is sponsoring clinical trial NCT02713334?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02713334 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI